Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

BACKGROUND: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30–40% of ER+BC will relapse despite tamoxifen treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Loi, Sherene, Haibe-Kains, Benjamin, Desmedt, Christine, Wirapati, Pratyaksha, Lallemand, Françoise, Tutt, Andrew M, Gillet, Cheryl, Ellis, Paul, Ryder, Kenneth, Reid, James F, Daidone, Maria G, Pierotti, Marco A, Berns, Els MJJ, Jansen, Maurice PHM, Foekens, John A, Delorenzi, Mauro, Bontempi, Gianluca, Piccart, Martine J, Sotiriou, Christos
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2008
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2423197/
https://ncbi.nlm.nih.gov/pubmed/18498629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2164-9-239
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados